Life Sciences

  • February 01, 2024

    Spinal Implant Maker Eyes Ch. 11 Wind-Down In Del.

    Biotechnology firm InVivo Therapeutics Corp. petitioned for Chapter 11 protection in Delaware's bankruptcy court Thursday, saying it intends to wind down after abandoning the development of its primary product, an implant to treat spinal cord injuries.

  • February 01, 2024

    Publicis Reaches $350M Opioid Settlement With All 50 States

    Publicis Health LLC settled a lawsuit on Thursday with all 50 U.S. states, the District of Columbia, and several U.S. territories for $350 million over claims that it helped exacerbate the opioid crisis through its work with Purdue Pharma, the manufacturer behind OxyContin.

  • February 01, 2024

    Cell Therapy Firm Kyverna Eyes $200M IPO As Pipeline Builds

    Autoimmune diseases-focused drug developer Kyverna Therapeutics Inc. on Thursday unveiled a price range for an estimated $200 million initial public offering, guided by Paul Hastings LLP and underwriters counsel Covington & Burling LLP, joining an IPO pipeline that has become more promising for life sciences firms.

  • January 31, 2024

    Fluoride Risk Trial Opens With Claim Exposure Drops Kids' IQ

    Environmental groups told a California federal judge during bench trial openings Wednesday that new studies show clear links between prenatal fluoride exposure and children's lower IQ levels, while the EPA defended current regulations allowing low levels of fluoride in drinking water and underscored that "the dose makes the poison."

  • January 31, 2024

    FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK

    A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of approximately 30,000 FibroGen investors who accused the company of making misleading statements about the safety of its anemia drug, citing the risk of recoverability issues due to FibroGen's financial state.

  • January 31, 2024

    FDA Adopts ISO Standard For Device Makers In New Rule

    The U.S. Food and Drug Administration has issued its final rule amending the good manufacturing practice requirements of the Quality System regulation to refer to an ISO standard that requires medical device makers to show they can meet customer and regulatory requirements.

  • January 31, 2024

    Cooley-Led Vaxcyte Prices $750M Public Offering

    Public vaccine developer Vaxcyte has priced a $750 million public offering of common stock and pre-funded warrants, represented by Cooley LLP, the company has announced.

  • January 31, 2024

    Cardinal Health Buys Specialty Networks In $1.2B Deal

    Healthcare services company Cardinal Health announced Wednesday that it has entered into a deal to buy health platform Specialty Networks for $1.2 billion in cash.

  • January 31, 2024

    Norton Rose-Led FibroBiologics Pulls Off Direct Listing

    Shares of drug developer FibroBiologics Inc. debuted in trading Wednesday after the chronic-disease focused company completed a direct listing, an alternative to a traditional initial public offering, represented by Norton Rose Fulbright LLP.

  • January 31, 2024

    Supernus Wins Ban On Generic Seizure Treatment

    A New Jersey federal judge has handed a win to Supernus Pharmaceuticals Inc. in its bid to bar a competitor from being able to market a generic version of a seizure drug called Trokendi XR for the time being.

  • January 31, 2024

    FDA Seeks Max Fines Against Shops Selling Esco Bars Vapes

    The U.S. Food and Drug Administration is looking to hit 21 retailers with civil penalties for selling the popular Esco Bars brand of vapes, according to an agency announcement, saying the brick-and-mortar shops knew the popular "youth appealing" brand lacked premarket authorization.

  • January 31, 2024

    NJ Law Firm Seeks Sanctions In Malpractice Suit Led By Rival

    Mazie Slater Katz & Freeman LLC asked a New Jersey federal judge on Wednesday to impose "a substantial monetary sanction" against former-colleague-turned-rival Bruce Nagel and his firm Nagel Rice LLP, arguing that their most recent filing in its legal malpractice suit alleging Mazie Slater overcharged clients in multidistrict litigation over the blood pressure drug Benicar contains frivolous claims and baseless conclusions.

  • January 31, 2024

    Gunderson Practice Head Boosts Orrick's Life Sciences Team

    Orrick Herrington & Sutcliffe LLP said Wednesday that it had hired its 34th life sciences partner in three years, welcoming the former head of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP's licensing, strategic partnering and commercial transactions group.

  • January 30, 2024

    Ex-Pfizer Compliance Officer Revamps Whistleblower Suit

    A former Pfizer compliance officer said he endured harassment and discrimination before being fired in retaliation for reporting the pharmaceutical giant to the U.S. Securities and Exchange Commission over concerns that it was potentially violating the Foreign Corrupt Practices Act, according to an amended complaint filed in California federal court.

  • January 30, 2024

    Scholars, Advocates Tell Justices Mifepristone Limits Must Go

    A mix of scholars, healthcare providers, lawmakers and abortion rights supporters filed three dozen amicus briefs Tuesday, urging the U.S. Supreme Court to reverse a Fifth Circuit decision that reinstated some restrictions on mifepristone, a drug used to end early pregnancies and manage miscarriages.

  • January 30, 2024

    1st Circ. Backs Doctor In Row Over Patent Evidence

    The First Circuit has backed a lower court jury's finding in favor of a doctor accused of fraud for not obtaining the proper consent from a patient who received an experimental therapy, rejecting an argument that the lower court didn't include evidence involving a patent.

  • January 30, 2024

    CDC Patent Apps Lead Gilead To Victory In HIV Research Feud

    The Centers for Disease Control and Prevention's repeated citation of research for HIV prevention treatments in its patent applications was key to the U.S. Court of Federal Claims concluding the government violated contracts with research partner Gilead, according to an opinion unsealed Tuesday.

  • January 30, 2024

    Trans Care Ban Poses 'Philosophical' Questions, Justices Say

    A Texas Supreme Court justice on Tuesday wondered if seven parents of transgender children were asking the court to resolve "a moral and philosophical question" behind gender identity as it weighed whether to uphold a state court judge's decision to block a law prohibiting minors from receiving gender-affirming care.

  • January 30, 2024

    Pharmacy Knew Conn. Kickbacks Broke Law, Founder Testifies

    The owners of a compounding pharmacy at the center of an $11 million drug kickback case knew that it was illegal to make payments to patients who got their prescriptions filled and recruited other customers, a Connecticut state court judge heard Tuesday before striking the witness testimony from the record.

  • January 30, 2024

    Can Brain Scans Build On Consumer Surveys In IP Disputes?

    Consumer surveys for trademark cases have faced criticism from judges over their objectivity, but a group of legal and neuroscience scholars say brain scans can bolster survey results by showing how people react when they see similar products.

  • January 30, 2024

    Philips Halts Sales Of Sleep Apnea Devices In US After Recall

    Koninklijke Philips NV revealed in a U.S. Securities and Exchange Commission filing Monday that it is halting sales of sleep apnea breathing machines in the U.S. after it began a recall in 2021 over potential health risks posed by the breakdown of sound-insulating foam.

  • January 30, 2024

    Milan Becomes 3rd Seat Of Unified Patent Court Division

    Milan will become the last seat of a trio for the central area of the European Union's Unified Patent Court system, after the United Kingdom bowed out of the role nearly four years ago.

  • January 30, 2024

    Pro Bono Patent Program Attracts Many Female Applicants

    The director of the U.S. Patent and Trademark Office claims that the agency's pro bono program has provided "over $39.3 million in donated legal services" since 2015 and noted on Tuesday that those free services have also seen "high participation rates" by female patent applicants.

  • January 30, 2024

    Allergan Asks 9th Circ. To Ignore Atty's Claims Of Fraud

    Allergan has urged the Ninth Circuit to uphold a California federal court's decision to toss a suit from a patent litigator concerning claims of fraudulently landing dementia drug patents, arguing that the conduct has been publicly disclosed, and that the litigator did not bring any new information to the appeal.

  • January 30, 2024

    7th Circ. Won't Revive School Staffers' COVID-Testing Suit

    The Seventh Circuit on Monday refused to reinstate a lawsuit brought by public school personnel challenging the Illinois governor's orders that they be tested regularly for COVID-19 unless they had been vaccinated, saying the plaintiffs improperly filed one suit in state court seeking declaratory and injunctive relief and a second in federal court seeking damages.

Expert Analysis

  • Breaking Down High Court's New Code Of Conduct

    Author Photo

    The U.S. Supreme Court recently adopted its first-ever code of conduct, and counsel will need to work closely with clients in navigating its provisions, from gift-giving to recusal bids, say Phillip Gordon and Mateo Forero at Holtzman Vogel.

  • How Purdue High Court Case Will Shape Ch. 11 Mass Injury

    Author Photo

    The U.S. Supreme Court's recent arguments in Harrington v. Purdue Pharma, addressing the authority of bankruptcy courts to approve nonconsensual third-party releases in Chapter 11 settlement plans, highlight the case's wide-ranging implications for how mass injury cases get resolved in bankruptcy proceedings, says George Singer at Holland & Hart.

  • Opinion

    Legal Profession Gender Parity Requires Equal Parental Leave

    Author Photo

    To truly foster equity in the legal profession and to promote attorney retention, workplaces need to better support all parents, regardless of gender — starting by offering equal and robust parental leave to both birthing and non-birthing parents, says Ali Spindler at Irwin Fritchie.

  • Managing ANDA Venue Issues As Del. And NJ Filings Rise

    Author Photo

    Delaware and New Jersey have prevailed as the primary forum for pharmaceutical litigation as more generic companies file abbreviated new drug applications, but this venue scheme presents traps for the unwary, and legislation may still be necessary to ensure fairness and predictability, say Timothy Cook and Kevin Yurkerwich at WilmerHale.

  • Series

    Writing Thriller Novels Makes Me A Better Lawyer

    Author Photo

    Authoring several thriller novels has enriched my work by providing a fresh perspective on my privacy practice, expanding my knowledge, and keeping me alert to the next wave of issues in an increasingly complex space — a reminder to all lawyers that extracurricular activities can help sharpen professional instincts, says Reece Hirsch at Morgan Lewis.

  • What Lawyers Must Know About Calif. State Bar's AI Guidance

    Author Photo

    Initial recommendations from the State Bar of California regarding use of generative artificial intelligence by lawyers have the potential to become a useful set of guidelines in the industry, covering confidentiality, supervision and training, communications, discrimination and more, say attorneys at Debevoise.

  • Industry Must Elevate Native American Women Attys' Stories

    Author Photo

    The American Bar Association's recent research study into Native American women attorneys' experiences in the legal industry reveals the glacial pace of progress, and should inform efforts to amplify Native voices in the field, says Mary Smith, president of the ABA.

  • The Fed. Circ. In Nov.: Factual Support And Appellate Standing

    The Federal Circuit's recent Allgenesis Biotherapeutics v. Cloud Break Therapeutics decision shows that appellate standing requires specific factual support, underscoring the necessary requirements for a patent challenger in an appeal from an inter partes review at the U.S. Patent and Trademark Office, say Jeremiah Helm and Sean Murray at Knobbe Martens.

  • White House Activity Is A Band-Aid For Regulating AI In Health

    Author Photo

    In the medium term, recent White House actions will have a greater impact on AI in the health care industry than Congress' sluggish efforts to regulate it, but ultimately legislation of AI's development and use in the health space will fall to Congress, say Wendell Bartnick and Vanessa Perumal at Reed Smith.

  • Understanding Discovery Obligations In Era Of Generative AI

    Excerpt from Practical Guidance
    Author Photo

    Attorneys and businesses must adapt to the unique discovery challenges presented by generative artificial intelligence, such as chatbot content and prompts, while upholding the principles of fairness, transparency and compliance with legal obligations in federal civil litigation, say attorneys at King & Spalding.

  • Kochava Ruling May Hint At Next Privacy Class Action Wave

    Author Photo

    The Southern District of California's recent ruling in Greenley v. Kochava and increasing complaints alleging that a consumer website is an illegal “pen register” due to the use of third-party marketing software tools foreshadow a new theory of liability for plaintiffs in privacy litigation, say attorneys at Crowell & Moring.

  • Forecasting The Impact Of High Court Debit Card Rule Case

    Author Photo

    John Delionado and Aidan Gross at Hunton consider how the U.S. Supreme Court's forthcoming ruling in a retailer's suit challenging a Federal Reserve rule on debit card swipe fees could affect agency regulations both new and old, as well as the businesses that might seek to challenge them.

  • Series

    ESG Around The World: Mexico

    Author Photo

    ESG has yet to become part of the DNA of the Mexican business model, but huge strides are being made in that direction, as more stakeholders demand that companies adopt, at the least, a modicum of sustainability commitments and demonstrate how they will meet them, says Carlos Escoto at Galicia Abogados.

  • Opinion

    FDA And Companies Must Move Quickly On Drug Recalls

    Author Photo

    When a drug doesn't work as promised — whether it causes harm, like eyedrops recalled last month by the U.S. Food and Drug Administration, or is merely useless, like a widely used decongestant ingredient recently acknowledged by the agency to be ineffective — the public must be notified in a timely manner, says Vineet Dubey at Custodio & Dubey.

  • The Case For Post-Bar Clerk Training Programs At Law Firms

    Author Photo

    In today's competitive legal hiring market, an intentionally designed training program for law school graduates awaiting bar admission can be an effective way of creating a pipeline of qualified candidates, says Brent Daub at Gilson Daub.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!